Intelligent Bio Solutions Expects to Report Fiscal Second Quarter 2026 Revenue Growth of Approximately 48% Year-Over-Year, Surpassing $2 Million in Total Revenue for First Half of Fiscal Year
Intelligent Bio Solutions (Nasdaq: INBS) expects preliminary unaudited fiscal Q2 2026 revenue to rise about 48% YoY, and fiscal H1 2026 total revenue to be approximately $2.01 million (up 36% YoY).
Rhea-AI Summary
Intelligent Bio Solutions (Nasdaq: INBS) expects preliminary unaudited fiscal Q2 2026 revenue to rise about 48% YoY, and fiscal H1 2026 total revenue to be approximately $2.01 million (up 36% YoY).
Reader sales are expected to increase ~104% YoY in Q2 while cartridge sales are up ~33% Q2 / 38% H1, with accessories/training also growing. Results are preliminary and subject to quarter-end close and Form 10-Q filing during the week of Feb 9, 2026.
Positive
- Fiscal Q2 revenue growth of ~48% YoY
- Fiscal H1 total revenue of $2.01 million (up 36% YoY)
- Reader unit sales growth of ~104% YoY in Q2
- Cartridge sales growth of ~33% Q2 / 38% H1
Negative
- Reported results are preliminary and unaudited, subject to adjustments after quarter-end close
- Absolute revenue remains modest at $2.01 million for H1, limiting scale benefits near term
Details
News Market Reaction – INBS
In the Feb 5 session, INBS declined 9.13%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- H1 FY26 revenue
- $2.01 million
- Total revenue expected for fiscal H1 2026, July–December 2025
- H1 YoY growth
- 36%
- Year-over-year increase in total revenue for fiscal H1 2026
- H1 cartridge growth
- 38%
- Year-over-year increase in cartridge sales, fiscal H1 2026
- H1 reader growth
- 50%
- Year-over-year increase in reader sales, fiscal H1 2026
- Q2 FY26 revenue growth
- 48%
- Expected year-over-year revenue increase, fiscal Q2 2026
- Q2 reader growth
- 104%
- Expected year-over-year increase in reader sales, fiscal Q2 2026
- Q2 cartridge growth
- 33%
- Expected year-over-year increase in cartridge sales, fiscal Q2 2026
- Q2 other sales growth
- 36%
- Expected year-over-year increase in accessories and training, fiscal Q2 2026
Historical Context
-
New clinical studies initiated to support FDA 510(k) submission.
-
Closing of $10.0M private placement with new warrants issued.
-
Announcement of $10.0M private placement and warrant issuance.
-
New manufacturing partner expected to cut costs and boost capacity.
-
Alliance with Vlepis to expand non-invasive screening and monitoring.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
razor-razorblade business model financial
form 10-q regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Expected record fiscal second quarter revenue increase driven by expanding customer base and strong growth across all product categories
Reader sales expected to post year-over-year growth of more than
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary, unaudited revenue results for the fiscal second quarter and first half 2026 ended December 31, 2025.
The Company expects to report strong revenue growth across all product categories for the three- and six-month periods ended December 31, 2025.
Six-Month Period (Fiscal H1 ’26, July - December 2025):
- Total revenue expected to be approximately
$2.01 million , representing a36% increase year-over-year - Sales of cartridges expected to increase approximately
38% year-over-year - Sales of readers expected to increase approximately
50% year-over-year - Other sales (accessories, training) expected to increase approximately
10% year-over-year
Three-Month Period (Fiscal Q2 ’26, October - December 2025):
- Revenue expected to increase approximately
48% year-over-year - Sales of cartridges expected to increase approximately
33% year-over-year - Sales of readers expected to more than double, increasing approximately
104% year-over-year - Other sales (accessories, training) expected to increase approximately
36% year-over-year
“We are very pleased with our expected results, showing strong second-quarter performance and reader sales more than doubling year-over-year," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "This expansion of our installed base is the foundation of our razor-razorblade business model, as each reader placement creates a long-term relationship that drives recurring cartridge revenue. The anticipated
The preliminary unaudited revenue results for the fiscal second quarter and first half 2026, ended December 31, 2025, are based on information available to management as of the date of this press release and are, therefore, subject to adjustments based on the Company’s completion of its quarter-end financial close process. The Company expects to disclose financial results for the fiscal second quarter and first half 2026 ended December 31, 2025, in its upcoming Quarterly Report on Form 10-Q, expected to be filed with the Securities and Exchange Commission during the week commencing February 09, 2026.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.
For more information, visit: https://ibs.inc/
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, statements regarding Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and collaborations, and secure regulatory clearance or approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, actual results may differ materially from those expressed or implied by such statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” and “approximately,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those described in Intelligent Bio Solutions’ public filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of the date of this release. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact
Intelligent Bio Solutions Inc.
info@ibs.inc
Investor & Media Contact
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.